Global Biosimilars/Follow-on-Biologics Market 2013-2020

1. Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

2. Report Description Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020. To Get details: http://www.bigmarketresearch.com/biosimilars-market Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market.

3. Report Description Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the biosimilars market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market.Europe was the first region to draft guidelines for approval of biosimilars in 2006.

4. Report Description Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA).Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/FilgrastimHexal and Nivestim/Pliva/Maynefilgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future.  For Purchase Enquiry: http://www.bigmarketresearch.com/report-enquiry/984

5. Report Description • Key Benefits • The study is segmented in a strategic divisions to gain deeper insights into the market dynamics and understand the competitive environment of the overall market  • Financial market forecast is provided for the next eight years by considering 2013 as the base year • Comprehensive and quantitative data about changing market trends, intensifying competition and opportunities in biosimilars market are provided to make better business decisions • Porter’s Five Forces model and SWOT analysis of the overall market is provided to help stakeholders gain strategic insights of the market • Deep dive analysis of key market players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market • Identification of key investment pockets for the biosimilars market is strategically dealt to assist the stakeholders.

6. Report Description • Key Deliverables • Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography. • MARKET BY TECHNOLOGY • Monoclonal Antibodies (MAb) Technology • Recombinant DNA Technology (rDNA technology) • Nuclear magnetic resonance (NMR) technology • Chromatography • Electrophoresis • Mass Spectrometry • Western Blotting • Bioassay • MARKET BY TYPES • Recombinant Non-Glycosylated Protein • Human Growth Hormone • Insulin

7. Report Description • Recombinant Glycosylated Protein • Erythropoietin • Monoclonal antibodies • Others • Peptides • Octreotide • Desmopressin • Cyclosporine • Calcitonin • Eptifibatide • LH-RH (Leuprolide) • Nesiritide • Teriparatide • Bivalirudin • Enfuvirtide • Glucagon

8. Report Description • MARKET BY APPLICATIONS • Blood disorders • Chemotherapy induce Anaemia • Hemophilia • Pulmonary embolism • Oncology diseases • Lungs cancer • Colorectal cancer • Breast cancer • Cervical cancer • Leukemia • Prostate cancer • Chronic and autoimmune diseases • Neutropenia • Multiple sclerosis • Cystic Fibrosis

9. Report Description • LRheumatoid arthritis (RA) • Acromegaly • Eprosy • Growth hormone deficiencies • Others • MARKET BY SERVICES • Contract Research and Manufacturing Services (CRAMS) • Clinical Trials • MARKET BY GEOGRAPHY • North America • Europe • Asia-Pacific • LAMEA

10. Table Of Content CHAPTER 1 INTRODUCTION CHAPTER 2 EXECUTIVE SUMMARY CHAPTER 3 MARKET OVERVIEW CHAPTER 4 GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY TECHNOLOGY CHAPTER 5 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE CHAPTER 6 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS CHAPTER 7 GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET BY SERVICES CHAPTER 8 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY GEOGRAPHIES CHAPTER 9 KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY CHAPTER 10 COMPANY PROFILES To Get Complete TOC Mail @ sales@bigmarketresearch.com

11. FOR MORE DETAILS Visit us at http://www.bigmarketresearch.com/biosimilars-market Stay With Us: